These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20006502)

  • 1. Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?
    Ochala J
    Neuromuscul Disord; 2010 Feb; 20(2):98-101. PubMed ID: 20006502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 3. Streptomycin and EDTA decrease the number of desmin-negative fibers following stretch injury.
    Willems ME; Stauber WT
    Muscle Nerve; 2005 Sep; 32(3):310-5. PubMed ID: 15948207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
    Bowman P; Haikala H; Paul RJ
    J Pharmacol Exp Ther; 1999 Jan; 288(1):316-25. PubMed ID: 9862786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a preferential myosin loss on Ca2+ activation of force generation in single human skeletal muscle fibres.
    Ochala J; Larsson L
    Exp Physiol; 2008 Apr; 93(4):486-95. PubMed ID: 18245202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium.
    Brixius K; Mehlhorn U; Bloch W; Schwinger RH
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1284-90. PubMed ID: 11082466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Ca2+ sensitizers on contraction, [Ca2+]i transient and myofilament Ca2+ sensitivity in diabetic rat myocardium: potential usefulness as inotropic agents.
    Ishitani T; Hattori Y; Sakuraya F; Onozuka H; Makino T; Matsuda N; Gando S; Kemmotsu O
    J Pharmacol Exp Ther; 2001 Aug; 298(2):613-22. PubMed ID: 11454923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ca2+ channels and skeletal muscle diseases.
    Lee EH
    Prog Biophys Mol Biol; 2010 Sep; 103(1):35-43. PubMed ID: 20553745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 11. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness.
    Ryall JG; Schertzer JD; Lynch GS
    Biogerontology; 2008 Aug; 9(4):213-28. PubMed ID: 18299960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.
    Hasenfuss G; Pieske B; Kretschmann B; Holubarsch C; Alpert NR; Just H
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S45-51. PubMed ID: 8907130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of new inotropic agents on Ca++ sensitivity of contractile proteins.
    Rüegg JC
    Circulation; 1986 Mar; 73(3 Pt 2):III78-84. PubMed ID: 2935329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
    Du CK; Morimoto S; Nishii K; Minakami R; Ohta M; Tadano N; Lu QW; Wang YY; Zhan DY; Mochizuki M; Kita S; Miwa Y; Takahashi-Yanaga F; Iwamoto T; Ohtsuki I; Sasaguri T
    Circ Res; 2007 Jul; 101(2):185-94. PubMed ID: 17556660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of calcium-sensitizing drugs.
    Haikala H; Linden IB
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S10-9. PubMed ID: 8907127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the role of Ca++ binding proteins as possible targets for Ca++ sensitizing agents.
    Herzig JW; Quast U
    Z Kardiol; 1992; 81 Suppl 4():49-55. PubMed ID: 1290306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological modulation of cardiac and vascular contractile protein function.
    Silver PJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S34-46. PubMed ID: 2433541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C Ca++ binding by MCI-154, a novel cardiotonic agent.
    Kitada Y; Kobayashi M; Narimatsu A; Ohizumi Y
    J Pharmacol Exp Ther; 1989 Jul; 250(1):272-7. PubMed ID: 2545860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of muscle ryanodine receptor calcium release channels by proteins in the sarcoplasmic reticulum lumen.
    Beard NA; Wei L; Dulhunty AF
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):340-5. PubMed ID: 19278523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the Ca2+ sensitizer EMD 57033 on intracellular Ca2+ in rat ventricular myocytes: relevance to arrhythmogenesis during positive inotropy.
    Kawai M; Lee JA; Orchard CH
    Clin Sci (Lond); 2000 Dec; 99(6):547-54. PubMed ID: 11099399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.